ADPT (Adaptive Biotechnologies) Accumulated Depreciation: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADPT Adaptive Biotechnologies Corp ADPT
65 GF Score
Price $24.19
GF Value $11.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Accumulated Depreciation?

Adaptive Biotechnologies ADPT -0.06% 65 Accumulated Depreciation is $0.0 Mil as of Jun. 2026. GuruFocus rates ADPT with a GF Score™ of 65/100 and a GF Value™ of $11.67 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Adaptive Biotechnologies's quarterly accumulated depreciation declined from Dec. 2025 ($-95.8 Mil) to Mar. 2026 ($0.0 Mil) but then stayed the same from Mar. 2026 ($0.0 Mil) to Jun. 2026 ($0.0 Mil).

Adaptive Biotechnologies's annual accumulated depreciation increased from Dec. 2023 ($-73.2 Mil) to Dec. 2024 ($-87.8 Mil) and increased from Dec. 2024 ($-87.8 Mil) to Dec. 2025 ($-95.8 Mil).

Adaptive Biotechnologies Accumulated Depreciation Related Terms

Adaptive Biotechnologies Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Accumulated Depreciation Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only -36.23 -54.35 -73.23 -87.82 -95.79

Adaptive Biotechnologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -95.79 0.00 0.00
ADPT
65GF Score
Adaptive Biotechnologies Corp ADPT
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adaptive Biotechnologies Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.0 Mil mean?
Adaptive Biotechnologies (ADPT) has a Accumulated Depreciation of $0.0 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Accumulated Depreciation too high?
Adaptive Biotechnologies' current Accumulated Depreciation is $0.0 Mil. Overall, Adaptive Biotechnologies has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Accumulated Depreciation compare to BLLN and GRAL?
Adaptive Biotechnologies' Accumulated Depreciation of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Diagnostics & Research company?
A good Accumulated Depreciation depends on the Medical Diagnostics & Research industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Accumulated Depreciation is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.67, compared to a current price of $24.19 — trading 107.3% above its estimated fair value. The current Accumulated Depreciation is $0.0 Mil. Adaptive Biotechnologies' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Accumulated Depreciation is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $24.19 is trading 107.3% above its estimated GF Value™ of $11.67. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

  • Accumulated Depreciation: $0.0 Mil
  • GF Value™: $11.67 vs. price of $24.19 (107.3% above fair value)
  • GF Score™: 65/100 with 6 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges 1HM:Germany
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
65GF Score

Get the complete analysis for ADPT

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.19
Price
$11.67
GF Value